BackTalis Biomedical Overview

Talis Biomedical Total Revenue

Track Talis Biomedical's total revenue ($300K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Jun 2024

Annual Revenue (TTM)

$300000.00
↓ 75.77% YoY

Trailing 12 months ending Jun 2024

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Talis Biomedical (TLIS) FAQ

Talis Biomedical (TLIS) currently reports a total revenue of $300K as of June 2024. That compares with $1.2M in the prior-year period — down 75.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Talis Biomedical's total revenue history and peer comparisons.

Talis Biomedical's total revenue decreased from $1.2M to $300K — a 75.8% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Talis Biomedical's total revenue of $300K is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Talis Biomedical reported $300K in total revenue as of June 2024. That compares with $1.2M in the prior-year period — down 75.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $300K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Talis Biomedical, and consider following TLIS for alerts when major investors trade the stock.